EOS imaging, a pioneer in orthopaedic 3D imaging, has announced that the U.S. Food and Drug Administration has approved hipEOS, a 3D hip arthroplasty planning software based on EOS stereo-radiographic 2D/3D imaging.
hipEOS is the first offering of a software portfolio associated with the EOS imaging system. Developed by OneFit medical, an EOS imaging group company, the software enables surgeons to perform, using EOS unique stereo-radiographic 2D/3D low dose images, pre-surgical planning including hip implant selection and virtual positioning in functional, weight-bearing 3D. The software takes full advantage of the bias-free, real size 3D patient anatomical information obtained from the EOS exam to help physicians define implant size and visualise pre-operatively the restoration expected from a total hip arthroplasty prior to surgery. hipEOS received a CE Mark in March 2014.
Hip arthroplasty is the first procedure that will be addressed with planning software utilising the advantages of EOS unique imaging. The Company intends to expand the suite of offerings to include additional orthopedic surgery planning software.
The hipEOS software will be officially launched in the U.S. at the American Academy of Orthopedic Surgeons Annual Meeting, March 24-28 in Las Vegas.
Marie Meynadier, CEO of EOS imaging, said, “hipEOS is the first step of our strategy to fully utilize EOS’ unique stereo-radiographic 2D/3D patient data in software tools that will help surgeons plan and execute precise surgical and non surgical treatments. We are very happy to have been granted market approval in the U.S. and to extend this offering, which has received a very positive feedback at the French SOFCOT launch in November, to our U.S. users and future users.”